Back to search

France· FR:66966299

NAGLAZYME 1 mg/ml, solution à diluer pour perfusion

A galsulfase product containing galsulfase, registered in France by BIOMARIN INTERNATIONAL LIMITED (IRLANDE). The same ATC class is registered in 14 of our 19 countries.

ATC A16AB08

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedNAGLAZYME 1 mg/ml, solution à diluer …ATCA16AB08REGISTER NO.FR:66966299PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Galsulfase is registered in 14 of 19 countries.

Countries holding a registration under ATC A16AB08 (galsulfase), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose

Galsulfase · ATC A16AB08

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
GALSULFASE
Manufacturer
BIOMARIN INTERNATIONAL LIMITED (IRLANDE)
Country
France (FR)
ATC code
A16AB08
ATC class
Galsulfase
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400956721870
    1 flacon(s) en verre de 5 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/65187734-9d03-458b-8b71-6d0516d6a9da
GET /v1/drugs/65187734-9d03-458b-8b71-6d0516d6a9da?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "66966299",
  "date_amm": "2006-01-24",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/05/324",
  "substance": "GALSULFASE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about galsulfase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.